Ignite Creation Date:
2024-05-05 @ 11:32 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00079846
Status:
TERMINATED
Last Update Posted:
2005-06-24
First Post:
2004-03-17
Brief Title:
Implitapide in Patients With Homozygous Familial Hypercholesterolemia HoFH on Maximal Concurrent Lipid-Lowering Therapy
Sponsor:
Medical Research Laboratories International
Organization:
Medical Research Laboratories International
Study Overview
Official Title:
Safety and Efficacy Study of Implitapide Compared With Placebo in Patients With Homozygous Familial Hypercholesterolemia HoFH on Maximal Concurrent Lipid-Lowering Therapy
Status:
TERMINATED
Status Verified Date:
2005-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if implitapide used in conjunction with other lipid-lowering therapies is safe and effective when compared to placebo in lowering low-density lipoprotein cholesterol LDL-C in patients with homozygous familial hypercholesterolemia HoFH
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None